Is it possible to sustain this rally? Biocryst Pharmaceuticals Inc. (BCRX) Stock
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
Stay away from Biocryst Pharmaceuticals Inc. (BCRX) Stock or get into it
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
Biocryst Pharmaceuticals Inc. (BCRX) Stock is more thoughtful than you think
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
Faced with a depressed economy, Biocryst Pharmaceuticals Inc. (BCRX) Stock offers an opportunity
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
Analysts Estimated Revenue of $86.29M in the current quarter for Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) Stock
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
With upside potential, Biocryst Pharmaceuticals Inc. (BCRX) Stock is well-positioned to grow
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
The idea of catching Biocryst Pharmaceuticals Inc. (BCRX) Stock might be a good one
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
The performance of Biocryst Pharmaceuticals Inc. (BCRX) Stock has improved
JP Morgan raised the price target for the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Overweight”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with […]
